{
    "nct_id": "NCT05648968",
    "official_title": "A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment",
    "inclusion_criteria": "* 18 years and older at time of signing consent\n* Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, who had an insufficient response to, or relapsed after at least one line of treatment, including patients with steroid resistance, dependence or intolerance\n* Hemoglobin concentration at screening and at Week 1 >=5 g/dL and <10 g/dL, associated with presence of symptoms related to anemia\n* The dose of supportive care must be stable for at least 4 weeks prior to randomization into the study\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* wAIHA secondary to hematologic disease involving bone marrow (e.g., CLL) or another immunologic disease requiring prohibited medication as per protocol. Patients with autoimmune diseases after wash-out from the treatments are allowed.\n* Presence of other forms of AIHA (cold or intermediate forms), Evans Syndrome or other cytopenias\n* Prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to randomization, or without hematological response to the last course of B-cell depleting therapy\n* Neutrophils: <1000/mm3\n* Serum creatinine >1.5 Ã— upper limit of normal (ULN)\n* Immunoglobulin G (IgG) <5g/L\n* Active viral, bacterial or other infections (including tuberculosis and SARS-CoV-2) requiring systemic treatment at time of screening, or history of recurrent clinically significant infection\n* Positivity for hepatitis C virus, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb). HBcAb positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given.\n* Known history of primary or secondary immunodeficiency, or a positive human immune deficiency virus (HIV) test result\n* Live or live-attenuated vaccination within 4 weeks before randomization\n* History of splenectomy\n\nOther protocol-defined Inclusion/Exclusion may apply.",
    "miscellaneous_criteria": "Key"
}